Tvax sets IPO range

Cancer company Tvax Biomedical Inc. (Lenexa, Kan.) amended its IPO and now plans to sell 2 million shares at $9-$11 per share. A $10 price would raise $20 million and value the company at $78.5 million. Roth Capital Partners; Cantor Fitzgerald; and Aegis are underwriters. Last November, Tvax filed to raise up to $40 million. ...